Notably, neuroinflammation is among the foremost events in AD pathogenesis.[18, 19, 20] CCL2 secretion is increased in AD patients and animal models.[21, 22] Therefore, the use of membranes with high expression of CCR2 for precise targeting of early‐stage lesions is a novel strategy for the effective treatment of AD. Here, CCR2 is linked to Alzheimer disease.